PTC Therapeutics has sold its rare pediatric disease priority review voucher (PRV) for $150 million, following FDA approval ...

The waiting time for Latin American patients with cancer, central nervous system disorders or rare diseases can take up to ...

A report from DelveInsight highlights over 20 companies developing 22 treatments for myotonic dystrophy, with progress in ...

Olverembatinib, developed by Ascentage Pharma, will be added to China’s National Reimbursement Drug List (NRDL) starting next ...

The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for ...

The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa ...

Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of ...

UK-based drugmaker Advanz Pharma has announced that following the grant of a temporary suspension, as announced on last month ...

The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of ...

The US Food and Drug Administration (FDA) yesterday announced its Fiscal Year 2025 Generic Drug User Fee Amendments (GDUFA).

Munich, Germany headquartered contract development and manufacturing organization (CDMO) Adragos Pharma has acquired Baccinex ...

Johnson & Johnson (J&J) has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies ...